Now, here's ANOTHER one. Actually a news report not just press release. If half this stuff is true..stock has got to take off one of these days.
8/25/98 Nymox's Urine Test For Alzheimer's Will Be Available By Year's
ROCKVILLE, Md. -(Dow Jones)- Canadian biopharmaceuticals maker Nymox
Pharmaceutical Corp. Tuesday said its urine test for Alzheimer's disease will be commercially available by the end of the year.
Nymox (NYMXF), which has a large research plant in Maryland, said the test is based on AD7C, a genetic marker for Alzheimer's disease.
The company says the gene produces a protein called Neuronal Thread
Protein, or NTP. Nymox already markets a test based on AD7C-NTP that
requires a spinal tap. The diagnostic tests don't require Food and Drug
Administration approval. Nymox is working on several new drug
candidates that it hopes may be developed into a treatment for the disease.The drugs are several years away from being marketed, but the company saidTuesday that it has "significantly advanced the process in its cell-biology laboratories for one of its key screening models for selecting and developing new Alzheimer's disease drug candidates."
The company said the "AD7C screening system is distinct" from its other drug development programs, such as those based on "spherons."
Nymox drew criticism from the medical community earlier this year when it said it had identified spherons, small structures in the brain, as a cause of Alzheimer's. Some researchers said that while the study was interesting, the company moved too quickly to label it a cause for the disease.
Alzheimer's is an incurable, degenerative disease of the brain that can cause dementia, memory loss, impaired speech, personality changes and eventually death. The disease is a hot sector in the pharmaceuticals field, as only two drugs so far have been approved, and they have shown only limited success in restoring some memory.
Copyright (c) 1998 Dow Jones & Company, Inc. |
